ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 589,71
0,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ESSA Pharma Inc (EPIX)

  7. ESSA Pharma Inc (EPIX) Actualités

EPIX

ESSA Pharma (EPIX)

ESSA Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EPIX
DateHeureSourceTitreSymboleSociété
30/05/202414h00PR Newswire (US)ESSA Pharma to Present at the Jefferies Global Healthcare ConferenceNASDAQ:EPIXESSA Pharma Inc
14/05/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EPIXESSA Pharma Inc
14/05/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EPIXESSA Pharma Inc
14/05/202413h00PR Newswire (US)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024NASDAQ:EPIXESSA Pharma Inc
06/05/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
09/04/202414h00PR Newswire (US)ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPIXESSA Pharma Inc
08/03/202402h13PR Newswire (Canada)ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSNASDAQ:EPIXESSA Pharma Inc
13/02/202413h00PR Newswire (US)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023NASDAQ:EPIXESSA Pharma Inc
06/02/202414h00PR Newswire (US)ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:EPIXESSA Pharma Inc
26/01/202422h40Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EPIXESSA Pharma Inc
26/01/202422h27Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EPIXESSA Pharma Inc
25/01/202416h00PR Newswire (US)ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumNASDAQ:EPIXESSA Pharma Inc
23/01/202422h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EPIXESSA Pharma Inc
16/01/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EPIXESSA Pharma Inc
12/12/202313h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EPIXESSA Pharma Inc
12/12/202313h00PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023NASDAQ:EPIXESSA Pharma Inc
21/11/202314h00PR Newswire (US)ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:EPIXESSA Pharma Inc
08/11/202314h00PR Newswire (Canada)ESSA Pharma to Present at the Jefferies London Healthcare ConferenceNASDAQ:EPIXESSA Pharma Inc
06/11/202323h51PR Newswire (Canada)ESSA Pharma Enters into At-The-Market Equity Offering Sales AgreementNASDAQ:EPIXESSA Pharma Inc
26/10/202323h41PR Newswire (Canada)ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific RetreatNASDAQ:EPIXESSA Pharma Inc
21/10/202315h00PR Newswire (US)ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 CongressNASDAQ:EPIXESSA Pharma Inc
11/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EPIXESSA Pharma Inc
03/10/202322h35Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:EPIXESSA Pharma Inc
19/09/202322h43Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:EPIXESSA Pharma Inc
18/09/202313h00PR Newswire (US)ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:EPIXESSA Pharma Inc
31/08/202313h00PR Newswire (Canada)ESSA Pharma Insiders Establish Automatic Securities Disposition PlansNASDAQ:EPIXESSA Pharma Inc
08/08/202313h00PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023NASDAQ:EPIXESSA Pharma Inc
06/06/202322h31Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:EPIXESSA Pharma Inc
06/06/202322h15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EPIXESSA Pharma Inc
06/06/202313h00PR Newswire (US)ESSA Pharma Appoints Lauren Merendino to its Board of DirectorsNASDAQ:EPIXESSA Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:EPIX

Dernières Valeurs Consultées

DBI
G947
XMIUE1C CHF INAV
TSXV
VPC
BOV
TSNF34R
Tyson Foods
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés